Publicacións (45) Publicacións de Luis Morano Amado

2022

  1. Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders

    Viruses, Vol. 14, Núm. 11

  2. Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations

    Future Virology, Vol. 17, Núm. 2, pp. 77-86

  3. Ten steps to eliminating hepatitis C in hospitals

    Nature Reviews Gastroenterology and Hepatology

2021

  1. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach

    Journal of the International Association of Providers of AIDS Care, Vol. 20

2020

  1. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32

2018

  1. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

    Gastroenterology, Vol. 155, Núm. 4, pp. 1120-1127.e4

  2. Hypochromic skin lesions in Brazilian patient

    Medicina Clinica, Vol. 151, Núm. 6, pp. e35

  3. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort

    Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706

  4. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

    HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30

2017

  1. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

    HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134

  2. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 5, pp. 853-861

  3. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Pulmonary sarcoidosis in the context of a telaprevir-based triple therapy for hepatitis C

    Revista Portuguesa de Pneumologia

  2. Significado clínico de las micobacterias ambientales aisladas en muestras respiratorias en pacientes con silicosis y sin silicosis

    Archivos de Bronconeumologia, Vol. 52, Núm. 3, pp. 145-150

2015

  1. Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy

    Revista Espanola de Enfermedades Digestivas

2008

  1. Anemia aplásica asociada a infección por el virus de la hepatitis C

    Anales de Medicina Interna

  2. Pancoast tumor with acropaquia and Claude-Bernard-Horner syndrome

    Medicina clínica, Vol. 131, Núm. 14, pp. 560

2007

  1. Primary adrenocortical insufficiency (Addison's disease) of probable tuberculous origin

    Medicina clínica, Vol. 129, Núm. 17, pp. 680

2006

  1. Patología orgánica en adicciones: Otras infecciones asociadas al consumo de drogas

    Adicciones: Revista de socidrogalcohol, Vol. 18, Núm. 1, pp. 137-159

2004

  1. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: A pharmacosurveillance study in Spain

    Clinical Microbiology and Infection, Vol. 10, Núm. 9, pp. 785-790